Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://www.ncbi.nlm.nih.gov/pubmed/26451328
http://dx.doi.org/10.1002/psp4.12014
_version_ 1782393200997040128
author Stroh, M
Carlile, DJ
Li, C-C
Wagg, J
Ribba, B
Ramanujan, S
Jin, J
Xu, J
Charoin, J-E
Xhu, Z-X
Morcos, PN
Davis, JD
Phipps, A
author_facet Stroh, M
Carlile, DJ
Li, C-C
Wagg, J
Ribba, B
Ramanujan, S
Jin, J
Xu, J
Charoin, J-E
Xhu, Z-X
Morcos, PN
Davis, JD
Phipps, A
author_sort Stroh, M
collection PubMed
description Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT.
format Online
Article
Text
id pubmed-4592528
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45925282015-10-08 Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue Stroh, M Carlile, DJ Li, C-C Wagg, J Ribba, B Ramanujan, S Jin, J Xu, J Charoin, J-E Xhu, Z-X Morcos, PN Davis, JD Phipps, A CPT Pharmacometrics Syst Pharmacol Perspective Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT. John Wiley & Sons, Ltd 2015-09 2015-09-11 /pmc/articles/PMC4592528/ /pubmed/26451328 http://dx.doi.org/10.1002/psp4.12014 Text en © 2015 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Perspective
Stroh, M
Carlile, DJ
Li, C-C
Wagg, J
Ribba, B
Ramanujan, S
Jin, J
Xu, J
Charoin, J-E
Xhu, Z-X
Morcos, PN
Davis, JD
Phipps, A
Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
title Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
title_full Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
title_fullStr Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
title_full_unstemmed Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
title_short Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
title_sort challenges and opportunities for quantitative clinical pharmacology in cancer immunotherapy: something old, something new, something borrowed, and something blue
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://www.ncbi.nlm.nih.gov/pubmed/26451328
http://dx.doi.org/10.1002/psp4.12014
work_keys_str_mv AT strohm challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT carliledj challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT licc challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT waggj challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT ribbab challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT ramanujans challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT jinj challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT xuj challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT charoinje challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT xhuzx challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT morcospn challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT davisjd challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue
AT phippsa challengesandopportunitiesforquantitativeclinicalpharmacologyincancerimmunotherapysomethingoldsomethingnewsomethingborrowedandsomethingblue

Ejemplares similares